

# View from the Advisory Council on Research, Care and Services for the National Alzheimer's Disease Plan



#DementiaCareSummit

## View From the Advisory Council on Research, Care and Services for the National Alzheimer's Plan

Ronald C. Petersen, PhD, MD

Cora Kanow Professor

of Alzheimer's Disease Research

Mayo Clinic College of Medicine

Rochester, MN

Research Summit on Dementia Care

NIH

October 16, 2017



©2017 MPMER | 3085094-04

## Disclosures

- Roche, Inc.
- Merck, Inc.
- Genentech, Inc.
- Biogen, Inc.
- Eli Lilly and Co.
- National Institute on Aging:
  - U01 AG006786
  - P50 AG016574
  - U01 AG011378
  - R01 AG011378
  - R01 AG041581
- GHR Foundation
- Mayo Foundation for Education and Research



©2017 MFMR | 3855094-35


Passed by Congress 2010	Advisory Council Appointed 2011	National Plan 2013	National Plan 2015	National Plan 2017
-------------------------------	--	--------------------------	--------------------------	--------------------------

### National Alzheimer's Project Act


Signed by President 2011	First National Plan 2012	National Plan 2014	National Plan 2016
--------------------------------	-----------------------------------	--------------------------	--------------------------




©2017 MFMR | 3855094-36



**National Plan  
to Address  
Alzheimer's Disease**


 U.S. Department of Health and Human Services

 <https://aspe.hhs.gov/national-plans-address-alzheimers-disease> ©2017 MPMER | 3885094-37

**NAPA**

**In the introductory language of the National Plan the term “Alzheimer’s Disease” is used but is intended to include AD related dementias:**

- Dementia with Lewy bodies**
- Frontotemporal lobar degeneration**
- Vascular cognitive impairment/dementia**
- Down syndrome**

 ©2017 MPMER | 3885094-38

## **NAPA Purpose**

- **Secretary of HHS shall**
  - **Create and maintain the National Plan**
  - **Coordinate Alzheimer's research and services across Federal agencies**
  - **Accelerate the development of treatments**
  - **Improve**
    - **Early diagnosis**
    - **Coordination of care and treatment**
  - **Ensure the inclusion of ethnic and racial populations at higher risk**
  - **Coordinate with international bodies**



©2017 MFMR | 385594-39

## **NAPA Advisory Council on Research, Care and Services**

- **Federal members**
  - **Centers for Disease Control and Prevention**
  - **Administration on Aging**
  - **Centers for Medicare & Medicaid Services**
  - **Indian Health Services**
  - **National Institutes of Health**
  - **Health Resources and Service Administration**
  - **National Science Foundation**
  - **Veterans Affairs**
  - **Food and Drug Administration**
  - **Agency for Healthcare Research and Quality**



©2017 MFMR | 385594-40



## **NAPA Advisory Council on Research, Care and Services**

- **Non-Federal Members – two each**
  - Patient advocates, including one person living with the disease
  - Caregivers
  - Health care providers
  - State health departments
  - Researchers
  - Voluntary health associations



©2017 MFMR | 3855094-41

## **US National Alzheimer's Plan Goals**

- 1. Prevent and effectively treat AD by 2025**
- 2. Enhance care quality and efficiency**
- 3. Expand supports for people with AD and families.**
- 4. Enhance public awareness/engagement**
- 5. Improve data to track progress**



©2017 MFMR | 3855094-42

## National Plan to Address Alzheimer's Disease



©2017 MFMR | 3855094-43


## The Process

- Summit
- Recommendations
- Milestones
- Concepts
- Approval of concepts
- Funding Opportunity Announcements




©2017 MFMR | 3855094-44

## National AD Plan Highlights



©2017 MFMR | 3885094-45

## AD/ADRD Research Increases at NIH



\* After FY2014, AD + ADRD  
 \*\* Estimated



©2017 MFMR | 3885094-46

## Can We Have an Impact on Care and Services in an Analogous Fashion?



©2017 MPMER | 3885094-47

## Research Issues Pertaining to Care and Services

- Can we slow progression of disease by care and service interventions?
  - Will behavioral treatments slow decline?
- Environmental impact
- Can we prolong symptomatic benefits?
- Interaction of pharmacological and non-pharmacological approaches
- Role of assistance to families



©2017 MPMER | 3885094-48



## Challenges in the Care and Services Arena

- Whereas with the AD and ADRD Summits, NIH was the overseeing agency
- Multiple agencies involved in care and services
- Therefore, the **Advisory Council on Alzheimer's Research, Care and Services** may need to play a key role in disseminating the recommendations and monitoring and coordinating efforts to move them forward



©2017 MFMR | 3885094-49

## Future of Care and Services Summits

- This likely will be just the first of Care and Services Summits
- AD and ADRD summits recur approximately every three years



©2017 MFMR | 3885094-50

# Thank You

- Co-chairs: Laura Gitlin, PhD; Katie Maslow
- Advisory Council members
- HHS ASPE team
  - Rohini Khillan
  - Linda Elam
  - Ruth Katz
  - Richard Frank
  - Don Moulds
  - Helen Lamont
  - Kara Townsend
  - John R. Graham

